Search Results - "Samyshkin Y"

Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis.

Authors: Atun, R A Samyshkin, Y Drobniewski, F et al.

Source: Health Policy & Planning. Sep2006, Vol. 21 Issue 5, p353-364. 12p.

This result is not displayed to guests.
Login for full access.

Seasonal variation and hospital utilization for tuberculosis in Russia: hospitals as social care institutions.

Authors: Atun, R. A. Samyshkin, Y. A. Drobniewski, F. et al.

Source: European Journal of Public Health. Aug2005, Vol. 15 Issue 4, p350-354. 5p. 1 Diagram, 2 Charts, 3 Graphs.

EPH134 Economic and Utility Evidence for Metastatic Synovial Sarcoma and Myxoid Round Cell Liposarcoma: A Systematic Literature Review.

Authors: Purser, M Samyshkin, Y Dodman, S et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS216-S216. 1p.

The Cost Burden of Community-Acquired Pneumonia in Russia in Adults of 50 and Older: A Regional Study and National Estimates.

Authors: Samyshkin, Y. Roberts, C.S. Koroleva, N. et al.

Source: Value in Health. Nov2014, Vol. 17 Issue 7, pA593-A593. 1p.

Resource Use And Outcomes Of Treatment Of Community-Acquired Pneumonia In Russia: A Retrospective Field Study.

Authors: Samyshkin, Y. Roberts, C.S. Koroleva, N. et al.

Source: Value in Health. May2014, Vol. 17 Issue 3, pA154-A154. 1p.

PDB50 Long-Term Clinical and Economic Benefit Associated with Liraglutide Versus Sitagliptin Therapy When Added to Metformin in the Treatment of Type 2 Diabetes: a Core Diabetes Model Study

Authors: Lee, W.C. Samyshkin, Y. Langer, J. et al.

Source: Value in Health. pA179-A179. 1p.

PRS45 Fully Incremental Cost-Effectiveness Analysis of Available Treatment Options in the Management of Severe COPD in the UK Setting

Authors: Kotchie, R. Samyshkin, Y. Hertel, N. et al.

Source: Value in Health. pA495-A495. 1p.

PRS39 Cost-Effectiveness of Roflumilast in Combination with Bronchodilator Therapies in Patients with Severe and Very Severe COPD in Switzerland

Authors: Samyshkin, Y. Radford, M. Schlunegger, M. et al.

Source: Value in Health. pA494-A494. 1p.

PCN87 The Cost Effectiveness of Cetuximab (Erbitux) in the Third Line Treatment of Metastatic Colorectal Cancer in the UK

Authors: Perard, R. Samyshkin, Y. Guillermin, A.L.G.

Source: Value in Health. pA450-A450. 1p.

PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients with Kras Wild-Type Tumours in the United Kingdom

Authors: Samyshkin, Y. Hertel, N. Griebsch, I.

Source: Value in Health. pA446-A447. 0p.

PRS18 THE COST-EFFECTIVENESS OF ROFLUMILAST IN THE MANAGEMENT OF SEVERE COPD IN THE UK SETTING

Authors: Kotchie, R. Samyshkin, Y. Zammit, D.C. et al.

Source: Value in Health. pA140-A140. 1p.

PCN182 Estimating the Number of US Patients with Multiple Myeloma (MM) at 5 or More Lines of Treatment (LOT).

Authors: Nikolaou, A. Maiese, E.M. Samyshkin, Y. et al.

Source: Value in Health. 2020 Supplement 2, Vol. 23, pS454-S455. 2p.

EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective.

Authors: Liu, T Purser, M Gong, C et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS112-S112. 1p.

Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit.

Authors: Baxter, M. Hudson, R. Mahon, J. et al.

Source: Diabetic Medicine. Nov2016, Vol. 33 Issue 11, p1575-1581. 7p. 4 Charts.

Evaluation Of The Pharmacy Budget Impact Of Alogliptin Plus Pioglitazone Fixed Dose Combination In The Treatment Of Type-2 Diabetes Mellitus.

Authors: Bron, M. Ferrufino, C.P. Samyshkin, Y. et al.

Source: Value in Health. May2013, Vol. 16 Issue 3, pA160-A160. 1p.

Health system frailties in tuberculosis service provision in Russia: an analysis through the lens of formal nutritional support.

Authors: Coker, R. J. Dimitrova, B. Drobniewski, F. et al.

Source: Public Health (Elsevier). Sep2005, Vol. 119 Issue 9, p837-843. 7p. 4 Graphs.

A framework and toolkit for capturing the communicable disease programmes within health systems.

Authors: Atun, R. A. Lennox-Chhugani, N. Drobniewski, F. et al.

Source: European Journal of Public Health. Sep2004, Vol. 14 Issue 3, p267-273. 7p. 3 Diagrams, 1 Chart.

Patient Heterogeneity In Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (Copd): are Current Models Suitable to Evaluate Personalized Medicine.

Authors: Hoogendoorn, M Feenstra, T Asukai, Y et al.

Source: Value in Health. Nov2015, Vol. 18 Issue 7, pA694-A694. 1p.

Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (COPD): Cross-Model Comparison of Hypothetical Treatment Scenarios.

Authors: Hoogendoorn, M. Feenstra, T. Asukai, Y. et al.

Source: Value in Health. Nov2014, Vol. 17 Issue 7, pA557-A558. 1p.